Role of matrix metalloproteinase 9 gene polymorphism as genetic risk factor for lung cancer

Ammar Adil Rashid; Rand Muhammed Abdul-Hussein Al-Husseini

doi:10.53730/ijhs.v6nS4.10232

Authors

Ammar Adil Rashid
ammara.salman@uokufa.edu.iq
Faculty of Science, University of Kufa, Iraq
Rand Muhammed Abdul-Hussein Al-Husseini Professor, Faculty of Science, University of Kufa, Iraq

Keywords:

lung cancer, MMP9 gene, Iraq

Abstract

Lung cancer (LC) is one of the most incident malignancies worldwide. This study investigated the potential role of matrix metalloproteinase9 gene (MMP9) single nucleotide polymorphisms (SNPs) in Lung cancer patients. The study population was included 75 Iraqi patients with confirmed Lung cancer and 25 healthy people as controls. In this study, the -1562 C/T polymorphism in MMP9 gene was detected by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) technique. The genotype distribution results of the -1562 C/T SNP of MMP9 gene have shown no significant differences (p>0.05) between controls (CC: n= 15, 60%; CT: n=9, 36%; TT: n=1, 4%) and Lung cancer patients (CC: n= 44, 58.66%; CT: n=30, 40%; TT: n=1, 1.34%). Results of the association analysis between genotype distribution of the -1562 C/T SNP of MMP9 gene and clinicopathological criteria of cases such as histological grading, TNM staging and lymph node metastasis, had shown no significant association (p>0.05). While analysis of the association between genotype distribution of the -1562 C/T SNP of MMP9 gene and smoking status among patients were statically significant (p<0.05). These results suggested that the SNP in MMP9 gene was involved in lung cancer progression, tissue invasion and metastasis involvement.

Downloads

Download data is not yet available.

References

Alberg, A. J., & Samet, J. M. (2003). Epidemiology of lung cancer. Chest, 123(1 Suppl), 21S–49S.

Allan, J. A., Docherty, A. J., Barker, P. J., Huskisson, N. S., Reynolds, J. J., & Murphy, G. (1995). Binding of gelatinases A and B to type-I collagen and other matrix components. The Biochemical journal, 309 ( Pt 1)(Pt 1), 299–306.

Al-Mosawi, A. J., (2020). The Pattern of Cancer in Iraq (2015-2018): An Overview. Archives of Oncology and Cancer Therapy, 3(2), 11-13.

Avci, N., Ture, M., Deligonul, A., Cubukcu, E., Olmez, O. F., Sahinturk, S., Topak, A., Kurt, E., Evrensel, T., Şahin, A. B., & Yakut, T. (2015). Association and Prognostic Significance of the Functional -1562C/T Polymorphism in the Promoter Region of MMP-9 in Turkish Patients with Gastric Cancer. Pathology oncology research: POR, 21(4), 1243–1247.

Bade, B. C., & Dela Cruz, C. S. (2020). Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clinics in chest medicine, 41(1), 1–24.

Banday, M. Z., Sameer, A. S., Mir, A. H., Mokhdomi, T. A., Chowdri, N. A., & Haq, E. (2016). Matrix metalloproteinase (MMP) -2, -7 and -9 promoter polymorphisms in colorectal cancer in ethnic Kashmiri population - A case-control study and a mini review. Gene, 589(1), 81–89.

Bauvois B. (2012). New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochimica et biophysica acta, 1825(1), 29–36.

Belinsky, S. A., Nikula, K. J., Palmisano, W. A., Michels, R., Saccomanno, G., Gabrielson, E., Baylin, S. B., & Herman, J. G. (1998). Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proceedings of the National Academy of Sciences of the United States of America, 95(20), 11891–11896.

Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., & Hanahan, D. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature cell biology, 2(10), 737–744.

Bhoopathi, P., Chetty, C., Gujrati, M., Dinh, D. H., Rao, J. S., & Lakka, S. S. (2010). The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. British journal of cancer, 102(3), 530–540.

Blankenberg, S., Rupprecht, H. J., Poirier, O., Bickel, C., Smieja, M., Hafner, G., Meyer, J., Cambien, F., Tiret, L., and AtheroGene Investigators (2003). Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 107(12), 1579–1585.

Blons, H., Pallier, K., Le Corre, D., Danel, C., Tremblay-Gravel, M., Houdayer, C., Fabre-Guillevin, E., Riquet, M., Dessen, P., & Laurent-Puig, P. (2008). Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC medical genomics, 1, 25.

Cao, S., Wendl, M. C., Wyczalkowski, M. A., Wylie, K., Ye, K., Jayasinghe, R., Xie, M., Wu, S., Niu, B., Grubb, R., 3rd, Johnson, K. J., Gay, H., Chen, K., Rader, J. S., Dipersio, J. F., Chen, F., & Ding, L. (2016). Divergent viral presentation among human tumors and adjacent normal tissues. Scientific reports, 6, 28294.

Chaudhary, A. K., Chaudhary, S., Ghosh, K., Shanmukaiah, C., & Nadkarni, A. H. (2016). Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia. Asian Pacific journal of cancer prevention: APJCP, 17(3), 1519–1529.

Clark, S. B., & Alsubait, S. (2020). Non-Small Cell Lung Cancer. In StatPearls. StatPearls Publishing.

Cronin, K. A., Lake, A. J., Scott, S., Sherman, R. L., Noone, A. M., Howlader, N., Henley, S. J., Anderson, R. N., Firth, A. U., Ma, J., Kohler, B. A., & Jemal, A. (2018). Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer, 124(13), 2785–2800.

Dinakar, C., & O'Connor, G. T. (2016). The Health Effects of Electronic Cigarettes. The New England journal of medicine, 375(14), 1372–1381.

Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature reviews. Cancer, 2(3), 161–174.

Elander, N., Söderkvist, P., & Fransén, K. (2006). Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer research, 26(1B), 791–795.

Ghaderian, S. M., Akbarzadeh Najar, R., & Tabatabaei Panah, A. S. (2010). Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coronary artery disease, 21(6), 330–335.

Gialeli, C., Theocharis, A. D., & Karamanos, N. K. (2011). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. The FEBS journal, 278(1), 16–27.

González-Arriaga, P., Pascual, T., García-Alvarez, A., Fernández-Somoano, A., López-Cima, M. F., & Tardón, A. (2012). Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC cancer, 12, 121.

Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer research, 54(18), 4855–4878.

Gupta, A., Zhou, C. Q., & Chellaiah, M. A. (2013). Osteopontin and MMP9: Associations with VEGF Expression/Secretion and Angiogenesis in PC3 Prostate Cancer Cells. Cancers, 5(2), 617–638.

Hecht S. S. (2003). Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nature reviews. Cancer, 3(10), 733–744.

Hemati, S., Sadeghi, M., Motovali-Bashi, M., Sahebi, A., & Malekshahi, Z. V. (2010). Higher plasma MMP-9 level in breast cancer patients with MMP-9 promoter T allele. Journal of Biological Research, 13, 113.‏

Hojilla, C. V., Mohammed, F. F., & Khokha, R. (2003). Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. British journal of cancer, 89(10), 1817–1821.

Hope, B. T., Nagarkar, D., Leonard, S., & Wise, R. A. (2007). Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers. The Journal of neuroscience : the official journal of the Society for Neuroscience, 27(8), 1964–1972.

Hu, C., Wang, J., Xu, Y., Li, X., Chen, H., Bunjhoo, H., Xiong, W., Xu, Y., & Zhao, J. (2013). Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene, 517(1), 65–71.

Huang H. (2018). Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel, Switzerland), 18(10), 3249.

Jassem, J., Jassem, E., Jakóbkiewicz-Banecka, J., Rzyman, W., Badzio, A., Dziadziuszko, R., Kobierska-Gulida, G., Szymanowska, A., Skrzypski, M., & Zylicz, M. (2004). P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma. Cancer, 100(9), 1951–1960.

Jiang, H., & Li, H. (2021). Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. BMC cancer, 21(1), 149.

Jumper, C., Cobos, E., & Lox, C. (2004). Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respiratory medicine, 98(2), 173–177.

Kiani, A., Kamankesh, M., Vaisi-Raygani, A., Moradi, M. R., Tanhapour, M., Rahimi, Z., Elahi-Rad, S., Bahrehmand, F., Aliyari, M., Aghaz, F., Mozafari, H., Rezvani, N., Haghnazari, L., & Pourmotabbed, T. (2020). Activities and polymorphisms of MMP-2 and MMP-9, smoking, diabetes and risk of prostate cancer. Molecular biology reports, 47(12), 9373–9383.

Klein, T., & Bischoff, R. (2011). Physiology and pathophysiology of matrix metalloproteases. Amino acids, 41(2), 271–290.

Köhrmann, A., Kammerer, U., Kapp, M., Dietl, J., & Anacker, J. (2009). Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC cancer, 9, 188.

Kubben, F. J., Sier, C. F., Meijer, M. J., van den Berg, M., van der Reijden, J. J., Griffioen, G., van de Velde, C. J., Lamers, C. B., & Verspaget, H. W. (2006). Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. British journal of cancer, 95(6), 744–751.

Li, H., Liang, X., Qin, X., Cai, S., & Yu, S. (2015). Association of matrix metalloproteinase family gene polymorphisms with lung cancer risk: logistic regression and generalized odds of published data. Scientific reports, 5, 10056.

Li, W., Jia, M. X., Wang, J. H., Lu, J. L., Deng, J., Tang, J. X., & Liu, C. (2019). Association of MMP9-1562C/T and MMP13-77A/G Polymorphisms with Non-Small Cell Lung Cancer in Southern Chinese Population. Biomolecules, 9(3), 107.

Libermann, T. A., & Zerbini, L. F. (2006). Targeting transcription factors for cancer gene therapy. Current gene therapy, 6(1), 17–33.

Lin, C. M., Zeng, Y. L., Xiao, M., Mei, X. Q., Shen, L. Y., Guo, M. X., Lin, Z. Y., Liu, Q. F., & Yang, T. (2017). The Relationship Between MMP-2 -1306C>T and MMP-9 -1562C>T Polymorphisms and the Risk and Prognosis of T-Cell Acute Lymphoblastic Leukemia in a Chinese Population: A Case-Control Study. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 42(4), 1458–1468.

Lin, T. S., Chiou, S. H., Wang, L. S., Huang, H. H., Chiang, S. F., Shih, A. Y., Chen, Y. L., Chen, C. Y., Hsu, C. P., Hsu, N. Y., Chou, M. C., Kuo, S. J., & Chow, K. C. (2004). Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncology reports, 12(4), 717–723.

Liu, D., Duan, W., Guo, H., Xu, X., & Bai, Y. (2011). Meta-analysis of associations between polymorphisms in the promoter regions of matrix metalloproteinases and the risk of colorectal cancer. International journal of colorectal disease, 26(9), 1099–1105.

Lu, L., Li, W., Liu, C., Jia, M., Xing, F., Jiang, P., & Tang, J. (2016). Association between-1562c/t polymorphisms in the matrix metalloproteinase-9 and the risk of lung cancer among south-central chinese population. Journal of Bionanoscience, 10(6), 506-510.‏

Mahmood, N. A., Abdulghany, Z. S., & Al-Sudani, I. M. (2019). The Expression Levels of Matrix Metalloproteinases Inhibitors TIMP1, TIMP2 and Matrix Metalloproteinases MMP2, MMP9 in Iraqi Patients Diagnosed with Colon Cancer. Govaresh, 24(3), 172-178.‏

Mahmood, N. A., Fakhoury, R. M., Yaseen, N. Y., & Moustafa, M. E. (2015). Matrix metalloproteinases MMP2 and MMP9 expression in stages II-III breast cancer in Iraqi women. Journal of Medical and Biological Science Research, 1(3), 30-37.‏

Masson, V., de la Ballina, L. R., Munaut, C., Wielockx, B., Jost, M., Maillard, C., Blacher, S., Bajou, K., Itoh, T., Itohara, S., Werb, Z., Libert, C., Foidart, J. M., & Noël, A. (2005). Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 19(2), 234–236.

Matsumura, S., Oue, N., Nakayama, H., Kitadai, Y., Yoshida, K., Yamaguchi, Y., Imai, K., Nakachi, K., Matsusaki, K., Chayama, K., & Yasui, W. (2005). A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. Journal of cancer research and clinical oncology, 131(1), 19–25.

Medley, T. L., Cole, T. J., Dart, A. M., Gatzka, C. D., and Kingwell, B. A. (2004). Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arteriosclerosis, thrombosis, and vascular biology, 24(8), 1479–1484.

Meng, J., Wang, S., Shen, X., Bai, Z., Niu, Q., Ma, D., Xu, Y., & Liang, C. (2018). Polymorphism of MMP-9 gene is not associated with the risk of urinary cancers: Evidence from an updated meta-analysis. Pathology, research and practice, 214(12), 1966–1973.

Nasr, H. B., Mestiri, S., Chahed, K., Bouaouina, N., Gabbouj, S., Jalbout, M., & Chouchane, L. (2007). Matrix metalloproteinase-1 (-1607) 1G/2G and -9 (-1562) C/T promoter polymorphisms: susceptibility and prognostic implications in nasopharyngeal carcinomas. Clinica chimica acta; international journal of clinical chemistry, 384(1-2), 57–63.

Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000). Matrix metalloproteinases: biologic activity and clinical implications. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 18(5), 1135–1149.

O'Farrell, T. J., & Pourmotabbed, T. (2000). Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase B. The Journal of biological chemistry, 275(36), 27964–27972.

Park, K. S., Kim, S. J., Kim, K. H., & Kim, J. C. (2011). Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. Journal of gastroenterology and hepatology, 26(2), 391–397.

Peng, B., Cao, L., Ma, X., Wang, W., Wang, D., & Yu, L. (2010). Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis, 25(4), 371–379.

Raeeszadeh-Sarmazdeh, M., Do, L. D., & Hritz, B. G. (2020). Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics. Cells, 9(5), 1313.

Rollin, J., Régina, S., Vourc'h, P., Iochmann, S., Bléchet, C., Reverdiau, P., & Gruel, Y. (2007). Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 56(2), 273–280.

Rydlova, M., Holubec, L., Jr, Ludvikova, M., Jr, Kalfert, D., Franekova, J., Povysil, C., & Ludvikova, M. (2008). Biological activity and clinical implications of the matrix metalloproteinases. Anticancer research, 28(2B), 1389–1397.

Sadeghi M, Motovali-Bashi M, Hojati Z. MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. Int J Integr Biol. 2009;6(1):33-37.

Salgia, R., & Skarin, A. T. (1998). Molecular abnormalities in lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 16(3), 1207–1217.

Savasoglu, K., & Emin Erdal, M. (2016). Association of MMP-2 (-1306 C>T), MMP-9 (-1562 C>T) Gene Polymorphism and the Formation of the Hematological Malignancies. Iranian journal of public health, 45(3), 392–393.

Schabath, M. B., & Cote, M. L. (2019). Cancer Progress and Priorities: Lung Cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 28(10), 1563–1579.

Sienel, W., Hellers, J., Morresi-Hauf, A., Lichtinghagen, R., Mutschler, W., Jochum, M., Klein, C., Passlick, B., & Pantel, K. (2003). Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. International journal of cancer, 103(5), 647–651.

Skřičková, J., Kadlec, B., Venclíček, O., & Merta, Z. (2018). Lung cancer. Karcinom plic. Casopis lekaru ceskych, 157(5), 226–236.

Slaton, J. W., Inoue, K., Perrotte, P., El-Naggar, A. K., Swanson, D. A., Fidler, I. J., & Dinney, C. P. (2001). Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. The American journal of pathology, 158(2), 735–743.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Takafuji, V., Forgues, M., Unsworth, E., Goldsmith, P., & Wang, X. W. (2007). An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene, 26(44), 6361–6371.

Thaib, P. K. P., & Rahaju, A. S. (2022). Clinicopathological profile of clear cell renal cell carcinoma. International Journal of Health & Medical Sciences, 5(1), 91-100. https://doi.org/10.21744/ijhms.v5n1.1846

Vairaktaris, E., Vassiliou, S., Nkenke, E., Serefoglou, Z., Derka, S., Tsigris, C., Vylliotis, A., Yapijakis, C., Neukam, F. W., & Patsouris, E. (2008). A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 34(4), 450–455.

Verma, S., Kesh, K., Gupta, A., & Swarnakar, S. (2015). An Overview of Matrix Metalloproteinase 9 Polymorphism and Gastric Cancer Risk. Asian Pacific journal of cancer prevention: APJCP, 16(17), 7393–7400.

Wang, L., Ma, Y. T., Xie, X., Yang, Y. N., Fu, Z. Y., Li, X. M., Liu, F., Huang, Y., Ma, X., Chen, B. D., Yuan, S., Sun, M. H., Peng, X., & Wang, B. Z. (2012). Interaction between MMP-9 gene polymorphisms and smoking in relation to myocardial infarction in a Uighur population. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 18(1), 72–78.

Wang, Y., Fang, S., Wei, L., Wang, R., Jin, X., Wen, D., Li, Y., Guo, W., Wang, N., & Zhang, J. (2005). No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung cancer (Amsterdam, Netherlands), 49(2), 155–161.

Webb, A. H., Gao, B. T., Goldsmith, Z. K., Irvine, A. S., Saleh, N., Lee, R. P., Lendermon, J. B., Bheemreddy, R., Zhang, Q., Brennan, R. C., Johnson, D., Steinle, J. J., Wilson, M. W., & Morales-Tirado, V. M. (2017). Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. BMC cancer, 17(1), 434.

West, K. A., Linnoila, I. R., Brognard, J., Belinsky, S., Harris, C., & Dennis, P. A. (2004). Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. Chest, 125(5 Suppl), 101S–2S.

Wogan, G. N., Hecht, S. S., Felton, J. S., Conney, A. H., & Loeb, L. A. (2004). Environmental and chemical carcinogenesis. Seminars in cancer biology, 14(6), 473–486.

Woo, M., Park, K., Nam, J., & Kim, J. C. (2007). Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. Journal of gastroenterology and hepatology, 22(7), 1064–1070.

Xing, L. L., Wang, Z. N., Jiang, L., Zhang, Y., Xu, Y. Y., Li, J., Luo, Y., & Zhang, X. (2007). Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World journal of gastroenterology, 13(34), 4626–4629.

Xu, E., Xia, X., Lü, B., Xing, X., Huang, Q., Ma, Y., Wang, W., & Lai, M. (2007). Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Molecular carcinogenesis, 46(11), 924–929.

Yu, Q., & Stamenkovic, I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes & development, 14(2), 163–176.

Zafari, F., & Sadeghi, M. (2021). The association between matrix metalloproteinases-9–1562 c/t polymorphism and lung cancer susceptibility: a systematic review and meta-analysis. Journal of Applied Biotechnology Reports, 8(1), 1-4.‏

Zhang, B., Ye, S., Herrmann, S. M., Eriksson, P., de Maat, M., Evans, A., Arveiler, D., Luc, G., Cambien, F., Hamsten, A., Watkins, H., & Henney, A. M. (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99(14), 1788–1794.

Zhang, J., Jin, X., Fang, S., Wang, R., Li, Y., Wang, N., Guo, W., Wang, Y., Wen, D., Wei, L., Dong, Z., and Kuang, G. (2005). The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis, 26(10), 1748–1753.

Zhang, L. F., Mi, Y. Y., Cao, Q., Wang, W., Qin, C., Wei, J. F., Zhou, Y. J., Li, Y. F., Tang, M., Liu, W. M., Zhang, W., & Zou, J. G. (2012). Update analysis of studies on the MMP-9 -1562 C>T polymorphism and cancer risk. Molecular biology reports, 39(4), 3435–3441.

Zheng, C., Wang, J., & Xie, S. (2021). Matrix metalloproteinase-9 -1562 C/T polymorphism is associated with the risk of sepsis in a Chinese population: A retrospective study. Innate immunity, 27(3), 260–265.

Zhou, P., Du, L. F., Lv, G. Q., Yu, X. M., Gu, Y. L., Li, J. P., & Zhang, C. (2011). Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast cancer research and treatment, 127(3), 813–818.

Zhu, X. M., & Sun, W. F. (2017). Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review. PloS one, 12(9), e0185456.